跳至主要内容
临床试验/EUCTR2011-000460-10-ES
EUCTR2011-000460-10-ES进行中(未招募)1 期

First year growth response associated geneticmarkers validation Phase IV open-label study inGrowth Hormone Deficient and Turner Syndromepre-pubertal children : the PREDICTPharmacogenetics Validation Study - PREDICT PGx Validation Study

Merck Serono S.A. Geneva0 个研究点目标入组 461 人开始时间: 2011年6月21日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
461

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Pre-established diagnosis of IGHD or TS based on classical criteria
  • with at least 1 year of r-hGH therapy and with Tanner stage 1 at
  • treatment start
  • Retrospective availability of a complete set of clinical, auxological
  • and biological parameters necessary for building the predictive
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 350
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 45
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Acquired GHD
  • Any drug or disease that could affect growth

研究者

发起方
Merck Serono S.A. Geneva

相似试验

Validation study for genetic markers for growth... | 临床试验